A5056889276- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Organ Transplantation Techniques and Outcomes
- Liver Diseases and Immunity
- Colorectal Cancer Screening and Detection
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal Transplantation Outcomes and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Alcohol Consumption and Health Effects
- HIV/AIDS drug development and treatment
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Systemic Lupus Erythematosus Research
- Vascular Anomalies and Treatments
- Abdominal vascular conditions and treatments
- Lung Cancer Research Studies
- Blood groups and transfusion
- Chronic Lymphocytic Leukemia Research
- Neuroendocrine Tumor Research Advances
- Diet and metabolism studies
- Hepatitis Viruses Studies and Epidemiology
- Diet, Metabolism, and Disease
Rutgers, The State University of New Jersey
1996-2025
Rutgers New Jersey Medical School
1996-2025
NewYork–Presbyterian Hospital
2003-2023
Columbia University
2003-2022
Columbia University Irving Medical Center
2016-2020
Presbyterian Hospital
2016-2020
Montefiore Medical Center
2008-2017
Albert Einstein College of Medicine
2008-2016
Florida State University
2012
New York Hospital Queens
2003-2006
Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There no proven effective treatment for sAH, which why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival subjects sAH. Adults bilirubin ≥8 mg/dL, Maddrey's discriminant function ≥ 32, Model End-Stage Liver Disease (MELD) score ≤ 35...
1. Hepatitis C is a global health problem affecting over 170 million people worldwide. 2. There wide geographic variation in both prevalence and genotype distribution of hepatitis virus on level. 3. Most spread parenterally, either through intravenous drug use or, lesser-developed countries, blood contamination during medical procedures. 4. leading cause end-stage liver disease hepatocellular carcinoma. 5. Despite declining incidence new infections, the burden disease, terms mortality cost,...
Histologic injury caused by recurrent hepatitis C virus (HCV) has been reported in up to 90% of HCV-infected patients who undergo liver transplantation with a cadaveric graft. However, the natural history HCV after living donor (LDLT) is not well described. We performed retrospective analysis 68 consecutive adult patients: 45 recipients grafts (CAD) were compared 23 LDLT patients. Elevated serum transaminases, positive RNA, and biopsy consistent histologic evidence defined recurrence. When...
With the development of all oral, interferon-free directly acting antiviral (DAA) medications, treatment hepatitis C virus (HCV) infection in renal transplant recipients is possible, but limited data exists on its safety and efficacy.We performed a retrospective cohort analysis patients transplanted at our center with HCV who have been started DAAs. Primary endpoints included sustained virologic response as defined negative viral load 12 weeks postcompletion therapy allograft function.A...
This observational study reports on a comprehensive nationwide evaluation of rising gastroenteropancreatic neuroendocrine tumor incidence in the US from 2001 to 2020.
Adolescents and adults with inherited disorders of coagulation have one the highest prevalence rates hepatitis C among known risk groups. Few data are available on use combination therapy interferon ribavirin in this population. Patients 13 years age older who were positive for virus (HCV) RNA by polymerase chain reaction negative human immunodeficiency randomized to receive alfa-2b (3 million units 3 times a week) plus (1,000 mg/day) or alone 48 weeks 24 posttreatment follow-up. started...
Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) 54%-63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent. The goal this study was to assess the effectiveness HCV treatment a treatment-naïve, human immunodeficiency (HIV)-negative, United States urban population many ethnic minority patients. We evaluated 2,370 outpatients for from 2001 2006...
The baseline prevalence of hepatitis C virus (HCV) and human immunodeficiency (HIV) coinfection among 2705 patients enrolled in HIV clinical trials the Community Programs for Clinical Research on AIDS (CPCRA) was 16.6%. For men, multivariate logistic regression showed that HIV-HCV positively associated with history injection drug use, older age, antiretroviral therapy naive status, African American or Latino ethnicity, no having sex men. No association found CD4+ cell count RNA level. HCV a...
Living donor liver transplantation evolved in response to shortage. Current guidelines recommend potential living donors (LD) have a body mass index (BMI) <30. With the current obesity epidemic, locating nonobese LD is difficult. From September 1999 August 2003, 68 with normal function test (LFTs) and without significant comorbidities underwent hepatectomy at our center. Post-operative complications were collected, including wound infection, pneumonia, hernia, fever, ileus, biliary leak,...
Patients with hepatocellular carcinoma (HCC) receive a higher MELD score and may undergo liver transplantation (OLT) earlier compared to patients cirrhosis, potentially decreasing waiting list mortality. However, post-OLT survival be reduced by recurrence of HCC. We clinical outcomes between HBV-cirrhosis no HCC HBV-HCC. A total 279 (HBV-cirrhosis = 183; HBV-HCC 96) in the US HBV-OLT study were followed for median 30.2 months from listing. older, more likely Asian, had less severe impairment...
Serologic testing shows that hepatitis C virus (HCV) may have a role in the pathogenesis of B-cell non-Hodgkin lymphomas (B-cell NHLs). We tried to demonstrate HCV RNA sequences paraffin-embedded tissue from NHLs by reverse-transcription double polymerase chain reaction (RT-PCR) and Southern blotting. studied 31 consecutive cases NHLs; lymph nodes 32 patients with diseases other than NHL were negative controls. Positivestrand was tested primers for 5′ untranslated region. Replicative strand...
The management of hepatitis B virus (HBV) and human immunodeficiency (HIV) coinfection is challenged by the selection patients for therapy, options antiviral medications, inconsistency in published treatment guidelines.A survey was sent to 161 sites a multicenter HIV clinical trials group assess HBV screening, criteria initiation choices coinfected with HIV.Of sites, 78 completed (response rate, 48.4%). Of these 98.7% screened infection, 86% vaccinated HIV-infected who were not immune 79%...
Social barriers to effective medical care are mandated be routinely assessed as part of an evaluation for liver transplantation. This study explores how frequently transplant programs encounter these in patients undergoing and whether with higher proportions Medicaid patients, historically disadvantaged minority rural social more frequently. A survey assessing patient demographics was electronically completed by representatives 61 104 eligible US adult (59%). Fifty-eight the identified...
Recurrent hepatitis C (HCV) and biliary complications (BC) are major causes of post liver transplant morbidity mortality. The impact these may be additive or synergistic. We performed a retrospective cohort study to analyze the effects HCV BC on all patients transplanted at two institutions over 6 years. was defined by imaging findings in setting abnormal function tests that required intervention. primary outcomes were graft patient survival mean 3.4 709 (619 deceased, 90 living donor)...
Summary Background Data about adverse events are needed to optimise telaprevir‐based therapy in a broad spectrum of patients. Aim To investigate patients with and without advanced fibrosis or cirrhosis real‐world setting. Methods on 174 hepatitis C‐infected initiating at Mount Sinai Montefiore medical centres were collected. Biopsy data FIB‐4 scores identified fibrosis. Multivariable fully adjusted models built assess the effect specific discontinuation treatment due an event. Results...
Despite a rapid evolution in the treatment of Hepatitis C (HCV), response to therapy among different racial and ethnic groups is poorly characterized.Three hundred thirty HCV infected patients naive previous received induction followed by every other day dosing with consensus interferon. Greater than 30% treated were not white, allowing comparison races/ethnicities genotypes.An overall sustained virologic (SVR) was achieved 24% 12% Hispanic, 4% AA (P = 0.003 white vs. non-white). 15% 13%...
There is an observed variation in the burden of hepatocellular carcinoma (HCC) across different US populations. Our study aims to comprehensively assess variations HCC incidence and mortality rates regions US. Understanding these geographical differences crucial, given prior evidence indicating viral hepatitis metabolic dysfunction-associated steatotic liver disease varying access curative treatment among states.
After liver transplantation, reinfection of the newly engrafted with hepatitis C virus is essentially universal in patients who are viremic at time transplantation. Treatment interferon preparations or without ribavirin recommended marked histologic injury; however, hematologic toxicity associated therapy has been reported, which usually treated growth factor support, including erythropoietin analogues. We present first reported case anti-erythropoietin antibody–mediated pure red cell...